Broncus Holding Corporation 2216.HK Stock
Broncus Holding Corporation Price Chart
Broncus Holding Corporation 2216.HK Financial and Trading Overview
Broncus Holding Corporation stock price | 0.58 HKD |
Previous Close | 1.2 HKD |
Open | 1.18 HKD |
Bid | 1.19 HKD x N/A |
Ask | 1.2 HKD x N/A |
Day's Range | 1.18 - 1.23 HKD |
52 Week Range | 1.08 - 3.06 HKD |
Volume | 655K HKD |
Avg. Volume | 489.71K HKD |
Market Cap | 585.96M HKD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.47 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.07 HKD |
2216.HK Valuation Measures
Enterprise Value | 445.48M HKD |
Trailing P/E | N/A |
Forward P/E | -4.8 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 62.24957 |
Price/Book (mrq) | 2.962963 |
Enterprise Value/Revenue | 47.326 |
Enterprise Value/EBITDA | -14.569 |
Trading Information
Broncus Holding Corporation Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -49.36% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.06 HKD |
52 Week Low | 1.08 HKD |
50-Day Moving Average | 1.59 HKD |
200-Day Moving Average | 1.97 HKD |
2216.HK Share Statistics
Avg. Volume (3 month) | 489.71K HKD |
Avg. Daily Volume (10-Days) | 456.4K HKD |
Shares Outstanding | 488.3M |
Float | 298.4M |
Short Ratio | N/A |
% Held by Insiders | 12.24% |
% Held by Institutions | 57.96% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -297.84% |
Operating Margin (ttm) | -347.47% |
Gross Margin | 77.71% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -8.61% |
Return on Equity (ttm) | -12.30% |
Income Statement
Revenue (ttm) | 9.41M HKD |
Revenue Per Share (ttm) | 0.02 HKD |
Quarterly Revenue Growth (yoy) | -22.90% |
Gross Profit (ttm) | 7.32M HKD |
EBITDA | -30577000 HKD |
Net Income Avi to Common (ttm) | -28036000 HKD |
Diluted EPS (ttm) | -0.48 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 188.24M HKD |
Total Cash Per Share (mrq) | 0.36 HKD |
Total Debt (mrq) | 1.47M HKD |
Total Debt/Equity (mrq) | 0.69 HKD |
Current Ratio (mrq) | 27.351 |
Book Value Per Share (mrq) | 0.405 |
Cash Flow Statement
Operating Cash Flow (ttm) | -30954000 HKD |
Levered Free Cash Flow (ttm) | -22320750 HKD |
Profile of Broncus Holding Corporation
Country | Hong Kong |
State | N/A |
City | Hangzhou |
Address | Building 8 |
ZIP | N/A |
Phone | N/A |
Website | https://www.broncus.com |
Industry | Medical Devices |
Sector(s) | Healthcare |
Full Time Employees | 376 |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy. In addition, the company provides diagnosis products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. The company was incorporated in 2012 and is headquartered in Hangzhou, China.
Q&A For Broncus Holding Corporation Stock
What is a current 2216.HK stock price?
Broncus Holding Corporation 2216.HK stock price today per share is 0.58 HKD.
How to purchase Broncus Holding Corporation stock?
You can buy 2216.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Broncus Holding Corporation?
The stock symbol or ticker of Broncus Holding Corporation is 2216.HK.
Which industry does the Broncus Holding Corporation company belong to?
The Broncus Holding Corporation industry is Medical Devices.
How many shares does Broncus Holding Corporation have in circulation?
The max supply of Broncus Holding Corporation shares is 488.62M.
What is Broncus Holding Corporation Price to Earnings Ratio (PE Ratio)?
Broncus Holding Corporation PE Ratio is now.
What was Broncus Holding Corporation earnings per share over the trailing 12 months (TTM)?
Broncus Holding Corporation EPS is -0.47 HKD over the trailing 12 months.
Which sector does the Broncus Holding Corporation company belong to?
The Broncus Holding Corporation sector is Healthcare.